First AD

Second AD

Neal Shore, MD, FACS, is the medical director for the Carolina Urologic Research Center

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Insights Video Series

Advancements in Targeting the Androgen Receptor Pathway in Prostate Cancer

OncLive Insights

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.